Detalles de la búsqueda
1.
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
Hepatology
; 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38652555
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
3.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983642
4.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol
; 2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38602340
5.
Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
Oncology
; 101(3): 193-202, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36649691
6.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
7.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
8.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
9.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
10.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020416
11.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
12.
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Oncologist
; 27(10): e774-e782, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35946841
13.
Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study.
Ann Surg Oncol
; 29(12): 7400-7406, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35857197
14.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology
; 100(2): 65-73, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34844247
15.
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Oncology
; 100(8): 449-459, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816996
16.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103846
17.
Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
BMC Cancer
; 22(1): 22, 2022 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34980017
18.
Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Pancreatology
; 22(8): 1159-1166, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150984
19.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35633504
20.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34799975